These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 36852651)
1. Effectiveness of mRNA and viral-vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. Zhang J; Yang W; Huang F; Zhang K J Med Virol; 2023 Mar; 95(3):e28623. PubMed ID: 36852651 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. Zeng B; Gao L; Zhou Q; Yu K; Sun F BMC Med; 2022 May; 20(1):200. PubMed ID: 35606843 [TBL] [Abstract][Full Text] [Related]
3. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766 [TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients. Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894 [TBL] [Abstract][Full Text] [Related]
5. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study). Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782 [TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant. Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006 [TBL] [Abstract][Full Text] [Related]
7. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Rahmani K; Shavaleh R; Forouhi M; Disfani HF; Kamandi M; Oskooi RK; Foogerdi M; Soltani M; Rahchamani M; Mohaddespour M; Dianatinasab M Front Public Health; 2022; 10():873596. PubMed ID: 36091533 [TBL] [Abstract][Full Text] [Related]
8. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age. Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946 [TBL] [Abstract][Full Text] [Related]
9. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
10. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers. Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506 [TBL] [Abstract][Full Text] [Related]
12. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Tartof SY; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM Lancet Respir Med; 2022 Jul; 10(7):689-699. PubMed ID: 35468336 [TBL] [Abstract][Full Text] [Related]
13. Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021. Winkelman TNA; Rai NK; Bodurtha PJ; Chamberlain AM; DeSilva M; Jeruzal J; Johnson SG; Kharbanda A; Klyn N; Mink PJ; Muscoplat M; Waring S; Yu Y; Drawz PE JAMA Netw Open; 2022 Mar; 5(3):e225018. PubMed ID: 35357452 [TBL] [Abstract][Full Text] [Related]
14. Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population. Butt AA; Talisa VB; Yan P; Shaikh OS; Omer SB; Mayr FB Clin Infect Dis; 2022 Aug; 75(1):e579-e584. PubMed ID: 35245940 [TBL] [Abstract][Full Text] [Related]
15. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073 [TBL] [Abstract][Full Text] [Related]
16. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999 [TBL] [Abstract][Full Text] [Related]
17. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis. Zou Y; Huang D; Jiang Q; Guo Y; Chen C Front Public Health; 2022; 10():940956. PubMed ID: 35910897 [TBL] [Abstract][Full Text] [Related]
18. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study. Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548 [TBL] [Abstract][Full Text] [Related]
19. Expert review on global real-world vaccine effectiveness against SARS-CoV-2. Chuenkitmongkol S; Solante R; Burhan E; Chariyalertsak S; Chiu NC; Do-Van D; Husin M; Hwang KP; Kiertiburanakul S; Kulkarni PS; Lee PI; Lobo RC; Nghia CH; Ong-Lim A; Sivasampu S; Suah JL; Tok PSK; Thwaites G; Expert Rev Vaccines; 2022 Sep; 21(9):1255-1268. PubMed ID: 35748494 [TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021. Machado A; Kislaya I; Rodrigues AP; Sequeira D; Lima J; Cruz C; Leite PP; Matias Dias C; Nunes B PLoS One; 2022; 17(9):e0274008. PubMed ID: 36099273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]